Radiation Oncology Research Presented at ASTRO
SAN FRANCISCO, November 6-7, 2001 - Following are highlights from research presented by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) during this week's annual meeting of the American Society for Therapeutic Radiation and Oncology (ASTRO).
High Dose Radiation Therapy Improves Survival in Patients with Mesothelioma
Mesothelioma, a rare but extremely lethal
type of lung cancer affecting the lining of the
lung, has always been a challenge to treat. A
new study finds that extensive surgery (removal
of the lung and the lining of the lung) followed
by high dose radiation therapy is well
tolerated, and may improve local disease control
and survival rates.
About 2,200 cases of mesothelioma are diagnosed
per year, the majority of which are caused by
environmental exposure to asbestos.
"For many years we were unable to give too
much radiation to the chest because of extreme
toxicity, but new technologies and treatment
techniques have helped us get around that," said
Santosh Yajnik, MD, radiation oncologist at
MSKCC and lead author of the study. One of the
reasons doctors were able to give higher doses
of radiation therapy to patients in this study
was because the affected lung had been
completely removed.
In the last four years, MSKCC has seen about 365
patients with mesothelioma, and approximately 63
patients were treated with this type of
extensive surgery. This experience makes the
Center one of only a handful of hospitals in the
country with expertise in this area.
In this study, 32 patients with various
stages of mesothelioma who had surgery at MSKCC
between 1990 and 2000 were treated with high
dose radiation therapy. The median overall
survival was 17 months compared to median
survival rates of about 12 months historically
seen in patients who have surgery alone.
Researchers noted that patients with earlier
stage disease experienced better survival rates
than those with late stage cancer. They also
observed that patients tolerated the treatment
well without suffering high levels of toxicity.
Four patients had local tumor recurrence, seven
had local and distant recurrence, and nine
patients had distant disease recurrence. "Now
that we know radiation helps with local control,
the next step is to study whether chemotherapy
can further reduce mortality rates and improve
distant control of the tumor," concluded Dr.
Yajnik.


